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SUMMARY 27 
Chronic kidney disease (CKD) increases fracture risk.  The results of this work point to changes 28 
in bone collagen and bone hydration as playing a role in bone fragility associated with CKD. 29 
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ABSTRACT 31 
Purpose/Introduction: Clinical data have documented a clear increase in fracture risk 32 
associated with chronic kidney disease (CKD).  Preclinical studies have shown reductions in 33 
bone mechanical properties although the tissue-level mechanisms for these differences remain 34 
unclear.  The goal of this study was to assess collagen cross-links and matrix hydration, two 35 
variables known to affect mechanical properties, in animals with either high or low turnover 36 
CKD.  Methods: At 35 weeks of age (>75% reduction in kidney function), the femoral diaphysis 37 
of male Cy/+ rats with high or low bone turnover rates, along with normal littermate (NL) 38 
controls, were assessed for collagen cross-links (pyridinoline (PYD), deoxypyridinoline (DPD), 39 
and pentosidine (PE)) using a high performance liquid chromatography (HPLC) assay as well as 40 
pore and bound water per volume (pw and bw) using a 1H nuclear magnetic resonance (NMR) 41 
technique.  Material-level biomechanical properties were calculated based on previously 42 
published whole bone mechanical tests.  Results: Cortical bone from animals with high turnover 43 
disease had lower Pyd and Dpd crosslink levels (-21% each), lower bw (-10%), higher PE 44 
(+71%), and higher pw (+46%), compared to NL.  Animals with low turnover had higher Dpd, PE 45 
(+71%), and bw (+7%) along with lower pw (-60%) compared to NL.  Both high and low turnover 46 
animals had reduced material-level bone toughness compared to NL animals as determined by 47 
three-point bending.  Conclusions: These data document an increase in skeletal PE with 48 
advanced CKD that is independent of bone turnover rate and inversely related to decline in 49 
kidney function.  Although hydration changes occur in both high and low turnover disease, the 50 
data suggest that non-enzymatic collagen crosslinks may be a key factor in compromised 51 
mechanical properties of CKD. 52 
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INTRODUCTION 57 
There are clear and consistent data showing that chronic kidney disease (CKD) is associated 58 
with an increased fracture risk compared to individuals without CKD [1-5].  More concerning is 59 
that individuals with CKD who experience a fracture are at greater risk of mortality compared to 60 
people without CKD who fracture [6, 7]. There are numerous challenges to reducing fracture risk 61 
in CKD patients because of the complexity in the underlying bone disease. CKD is associated 62 
with significant metabolic derangements, including secondary hyperparathyroidism, yet some 63 
patients have low levels of parathyroid (PTH) for unclear reasons [1, 8, 9].  At the skeletal level, 64 
CKD appears to have a preferential impact on cortical bone, leading to increased porosity, and 65 
likely playing a major role in fracture [10-14].  Preclinical studies have documented CKD-66 
associated reductions in biomechanical properties of whole bones, as well as at the micro- and 67 
nano-scale levels of the hierarchical organization of bone [14-18].  Properties of the tissue, such 68 
as mineral content, have not shown clear differences between normal and diseased bone 69 
leaving a cloud of uncertainty as to what properties of the tissue are responsible for this 70 
compromised mechanical phenotype associated with CKD [16]. 71 
 Increased attention to ‘bone quality’ (those aspects other than BMD that account for a 72 
bone’s resistance to fracture) has led to a greater understanding of various skeletal properties 73 
[19-21].  Collagen plays a vital role in bone with changes in collagen cross-links showing clear 74 
influence on bone mechanical properties [22-26]. CKD-induced collagen changes have been 75 
noted in serum and several soft-tissues [27] but data in bone are limited [28, 29].  A less often 76 
discussed bone quality variable, bone hydration, also affect bone mechanical properties [30-32], 77 
but only recently has it become clear that in vivo modulation of hydration can play a role in a 78 
bone’s fracture resistance capacity [33-35].      79 
 While there is an increasing awareness of the importance of bone quality in CKD [20, 80 
21], few studies have explicitly examined material properties in animal models [14-16, 18, 29]. 81 
The goal of the present study was to examine two specific properties, collagen crosslinks and 82 
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matrix hydration (bound and pore water) in a rat model with progressive development of CKD 83 
that can be manipulated to have either high or low turnover disease [14, 36]. We hypothesized 84 
that CKD adversely affects both collagen cross-links and matrix hydration, that these 85 
parameters would be most affected in high turnover disease, and there would be relationships 86 
between these properties and bone mechanical outcomes. 87 
 88 
MATERIALS AND METHODS 89 
Animal Model 90 
The current study utilized a slowly progressive animal model of CKD, the Cy/+ rat, which has 91 
been described in detail several times [15, 16, 18, 36-38]. Tissues analyzed in the current study 92 
were from select groups of animals that were part of a larger study [14].  Specifically, the 93 
animals were in one of three groups: Cy/+ animals that were untreated and thus had high 94 
turnover bone disease, Cy/+ given calcium supplementation in their drinking water to suppress 95 
PTH starting at 25 weeks of age (low turnover disease), or normal littermate controls (n=8-96 
10/gp).  All animals were euthanized at 35 weeks of age and femora (used to study both 97 
outcome measures) were saved wrapped in saline soaked gauze at -20C.  Prior to the assays 98 
reported in this paper, femora were tested in 3 point bending [14]. Blood was also collected at 99 
the end of the experiment for biochemical analyses.  Dynamic histomorphometry (detailing 100 
turnover rates), 3 point bending, and biochemical assays have all been previously reported [14].   101 
All procedures were conducted under the approval of Indiana University School of Medicine 102 
Institutional Animal Care and Use Committee protocol # 10479. 103 
 104 
Collagen Cross-Linking 105 
Segments of the femoral diaphysis (~3 mm in length) were processed for collagen cross-links 106 
as previously described [16].  Briefly, following demineralized in 20% EDTA (0.68 M, pH 7.4), 107 
demineralized bone was hydrolyzed. Each hydrolysate was resuspended in ultrapure water, 108 
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split into two equal portions, and dried. Half the residue was resuspended in ultrapure water with 109 
an internal standard (5 x 10-6 g/L pyridoxine) and assayed by a high performance liquid 110 
chromatography (HPLC) system (Beckman-Coulter System Gold 168). Standards with varying 111 
concentrations of pyridinoline (Pyd) (Quidel), deoxypyridinoline (Dpd) (Quidel), pentosidine (PE) 112 
(International Maillard Reaction Society), and a constant amount of pyridoxine were also 113 
assayed. Using a Waters 2475 fluorescence detector (excitation/emission of 295/400 nm for 114 
Pyd and Dpd and 328/378 nm for PE), chromatograms were recorded to determine the amount 115 
of each crosslink. These amounts were then normalized by collagen content (hydroxyproline), 116 
which was determined from the other half of each hydrolysate by another HPLC assay. The 117 
calculated mass of hydroxyproline was then multiplied by 7.5 (assuming 13-14% of type I 118 
collagen by mass) and divided by the molecular weight of collagen (30,000 Da), thereby giving 119 
crosslink concentration as mol/mol of collagen.   For each chromatogram, the area of the peak 120 
is calculated and divided by an internal standard. These values are then plotted onto a standard 121 
curve that plots the known masses of the standards to their given areas, providing an estimate 122 
of the mass of the given molecule in the unknowns (hydroxyproline, pyridinoline, 123 
deoxypyridinoline, and pentosidine). 124 
 125 
1H Nuclear magnetic resonance spectroscopy (NMR) 126 
A ~5 mm cross-section of the femur mid-shaft was placed into a low proton, loop-gap-style 127 
radio-frequency (RF) coil [39] along with a reference microsphere of water (T2 ~ 2 s). The NMR 128 
analysis to separate proton signals within the bone was then performed in a 4.7T horizontal-129 
bore magnet (Varian Medical Systems, Santa Clara, CA) using 90°/180° RF pulses of ~ 9/18 μs 130 
duration and collecting Carr-Purcell-Meiboom-Gill (CPMG) measurements with 10,000 echoes 131 
at 100 μs spacing. To generate the spectrum of transverse relaxation time constants (T2), the 132 
echo magnitudes were fitted with multiple exponential decay functions [40]. Upon normalizing 133 
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the integrated areas of bound water (T2 = 100 μs-800 μs) and pore water (T2 = 800 μs  – 600 134 
ms) to the area of the reference (T2 = 600 ms-10 s) [41], the volume of bound water and the 135 
volume of pore water were divided by the specimen volume (calculated from Archimedes’ 136 
principle) to give bound water (bw) and pore water (pw) volume fractions. 137 
 138 
Material-level biomechanical properties 139 
Whole bone material properties, determined using 3 point bending of the femora, have been 140 
previously reported [14].  Material-level properties were estimated using standard beam theory 141 
equations [30].  Bone diameters were measured at the mid-diaphysis using digital calipers while 142 
cross-sectional moment of inertia was measured using micro computed tomography.  143 
 144 
Statistical Analysis 145 
All analyses were performed using SAS software. Comparisons among the groups were made 146 
using student’s t-tests as the focus of this work was to independently assess high/lower turnover 147 
conditions versus control.  Pearson product moment correlation tests were used to assess the 148 
relationship between variables across all treatments with the exception of hydration for which 149 
Spearman correlations were used, as the data were not normally distributed.  A priori -levels 150 
were set at 0.05 to determine significance. 151 
 152 
RESULTS 153 
High-turnover CKD model 154 
Details about the phenotype of these animals with secondary hyperparathyroidism have been 155 
previous published [14].  Briefly, measures of kidney function and PTH were both significantly 156 
higher compared to normal (+200 and 2800%, respectively), indicative of active disease. 157 
Trabecular bone turnover, measured by dynamic histomorphometry, was more than 4-fold 158 
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higher in compared normal; cortical porosity was more than doubled.  Structural biomechanical 159 
properties, ultimate load and stiffness, were both significantly lower than controls with no 160 
difference in energy to fracture, a biomechanical property that is not independent of bone 161 
structure [14]. 162 
 All measured forms of collagen cross-links were significantly different compared to 163 
normal.  The two mature enzymatic cross-links, Pyd and Dpd were both significantly lower (-164 
21%; p = 0.004 and 0.02) compared to control (Figure 1A).  There was no significant difference 165 
in the Pyd/Dpd ratio.  PE, an advanced glycation product, was 71% (p = 0.001) higher 166 
compared to normal (Figure 1B).  Pore water volume fraction within the femoral cortex was 167 
higher (+46%: p = 0.024) while matrix bound water volume fraction was significantly lower (-168 
10%: p = 0.04) compared to normal animals (Figure 1C).  169 
 Ultimate stress was significantly lower than normal animals (-22%; p=0.001) with no 170 
difference in modulus and a trend toward lower toughness (-21%; p = 0.11) (Table 1). 171 
 172 
Low-turnover CKD model 173 
Details about the phenotype of these animals, where PTH is suppressed with the administration 174 
of calcium in the drinking water, have been previous published [14].  Briefly, measures of kidney 175 
function were significantly higher (+150%), while PTH was significantly lower (-75%) compared 176 
to normal. Trabecular bone turnover, cortical porosity, and structural properties were not 177 
different from controls. 178 
 Levels of Pyd in the bone matrix were not different from controls, while Dpd levels were 179 
significantly higher (+24%; p = 0.002) compared to normal (Figure 2A).  There was no 180 
significant difference in the Pyd/Dpd ratio.  PE was 72% higher (p = 0.001 compared to normal 181 
(Figure 2B).  The NMR-derived pore water within the femoral cortex was lower (-60%: p = 182 
0.001), and bound water was significantly higher (7%: p = 0.04) compared to normal animals 183 
(Figure 2C).  184 
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 Toughness was significantly lower than normal animals (-27%; p = 0.005) (Table 1).  185 
Ultimate stress and modulus were similar to normal animals. 186 
 187 
Correlations 188 
To examine relationships between outcome measures, correlations were assessed across the 189 
entire data set (controls, low turnover CKD and high turnover CKD). Kidney function (assessed 190 
by BUN) was significantly correlated to PE (R = 0.68) (Figure 3A).  PTH was significantly 191 
correlated to several outcomes including pore water (R= 0.81), bound water (R = -0.70), pyd (-192 
0.58), Dpd (R = -0.72), and PE (R = 0.46).  PE levels were negatively correlated to ultimate 193 
stress and toughness (R = -0.44 and -0.57, respectively) (Figure 3B).   194 
 195 
DISCUSSION 196 
It is becoming clear that the increased risk of skeletal fracture associated with chronic kidney 197 
disease is multi-factorial and occurs due to changes in both bone quantity and quality [12, 20, 198 
21, 42].  We have previously documented in an animal of progressive kidney disease, that 199 
compromised biomechanical properties can be quantified at the whole bone level as well as at 200 
the micro- and nano-scales [16].  These data illustrate that loss of bone mass, as has been 201 
repeatedly documented in both clinical and preclinical studies, is just one piece of the CKD 202 
fracture risk puzzle.  Given the nano-scale changes in bone mechanical properties, our 203 
laboratory has focused on measuring properties of the tissue matrix that contribute to this level 204 
of mechanical integrity [16].  The results of the current work, in a preclinical animal model of 205 
progressive CKD, point to modification of both collagen crosslinking and bone hydration in late 206 
stage CKD.  The changes in crosslinks confirm previous preclinical work in a different CKD 207 
model of high turnover bone [29], while the hydration data results represent novel data and a 208 
potential variable that could be used for non-invasive clinical assessment of bone quality  [33, 209 
43]. 210 
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 Collagen crosslinks in bone are either enzymatically-mediated (via lysyl oxidase) or non-211 
enzymatically mediated (in the form of advanced glycation end products (AGEs) such as 212 
pendosidine) [22].  The predominant mature enzymatic crosslinks − pyridinoline and 213 
deoxypyridinoline (also known as hydroxylyslpyridinoline and lyslpyridinoline, respectively) − 214 
have been shown to be associated with changes in bone mechanical properties [22].  Previous 215 
work by our lab in the same animal model as the current study showed no difference in Pyd or 216 
Dpd in CKD animals at 30 weeks [16].  We have documented that this animal model has rapid 217 
disease progression, in high-turnover states, between 30 and 35 weeks of age [14, 15], leading 218 
us to hypothesize that major changes in collagen cross-links might manifest with progression to 219 
advanced disease. Although this turned out to be the case, the story is more complicated as the 220 
enzymatic crosslink changes were dependent of rate turnover; high turnover groups had 221 
reduced enzymatic cross-links while low turnover animals had higher than normal levels of Dpd.    222 
The simplistic relationship between bone turnover and collagen crosslinks is an inverse 223 
one.  High bone turnover leads to lower levels of mature enzymatic crosslinks because the 224 
mean tissue age is lower; while low turnover bone typically has high levels.  Yet this relationship 225 
model assumes that the process of collagen crosslinks formation/maturation is not disrupted.  226 
Levels of lysyl oxidase, the key enzyme involved in enzymatic crosslinking, are tissue-specific.  227 
Kidney levels of lysyl oxidase have been shown to be higher in CKD and this is associated with 228 
increased fibrosis in renal tissue [44].  Serum measures of pyridinoline have been shown to be 229 
increased in patients with end stage renal disease, and these levels were higher in patients with 230 
high turnover compared to those with low turnover [45].  Yet these serum measures do not 231 
provide insight into skeletal levels, as the latter are determined both the rate of 232 
formation/breakdown (i.e., bone turnover) and the rate of crosslink maturation (i.e., divalent to 233 
trivalent bonded).  Skeletal levels of mature crosslinks have been found to be lower in patients 234 
with high-turnover end stage renal disease [27], while animal models of low turnover have 235 
shown reductions in bone lysyl oxidase levels [28].  Reduction in lysyl oxidase would reduce 236 
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enzymatic cross-links – although neither the clinical nor preclinical study measured both 237 
enzyme and crosslinks. Unfortunately, levels of lysyl oxidase were not assessed in the current 238 
work and thus definitive mechanisms underlying changes in mature cross-links cannot be 239 
ascertained. 240 
 Clinical studies have demonstrated that non-enzymatic cross-links (pentosidine, 241 
specifically) are increased in the circulation and soft tissue of patients with CKD [46].  Increased 242 
oxidative stress in CKD leads to increased production of AGE, and AGEs worsen oxidative 243 
stress creating a vicious cycle that is independent of blood glucose levels [47].  Skeletal levels 244 
of AGEs have been shown to be elevated in a small clinical study in patients on dialysis [27]. 245 
Although we have recently shown that at 30 weeks of age there is no difference in skeletal 246 
AGEs in our progressive CKD model, the current results show that at 35 weeks there is a 247 
striking difference (>70% higher than normal).  This suggests that, like the enzymatic cross-248 
links, major changes occur between 30 and 35 weeks in this animal model. More interesting is 249 
that the levels of AGEs in the bone are independent of bone remodeling rate – both high and 250 
low turnover models had similarly higher AGE levels compared to controls (Figures 1B and 251 
2B).  AGEs are typically linked to mean tissue age – since they accumulate in tissues over time 252 
when mean tissue age is higher AGEs are higher.  It therefore follows that, in normal situations, 253 
bone with higher turnover rates will have lower AGEs compared to bone with lower turnover 254 
rates.  This does not seem to hold true in the setting of CKD suggesting there is some intrinsic 255 
aspect of the disease that results in more AGE accumulation in bone independent of tissue age, 256 
perhaps due to ongoing AGE production in CKD [47] and reduced  clearance by the kidney [48].  257 
We hypothesize that elevations in oxidative stress may be underlying the accumulation of AGEs 258 
in this model.  Thus, the severity of kidney disease may be more important than the level of 259 
bone turnover for determination of skeletal AGEs.  The importance of the severity of kidney 260 
function is supported by a modest positive correlation between serum BUN and skeletal 261 
pentosidine (R = 0.679) in the current study (Figure 3A). 262 
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The influence of hydration on bone mechanical properties has long been appreciated as 263 
it pertains to ex vivo mechanical testing [30, 31].  More recently data have emerged showing 264 
modulation of hydration can occur in vivo [34], suggesting that it could play a role in disease-265 
related bone mechanical phenotypes.  The results of the current study show that in high 266 
turnover disease, pore water is significantly higher, while in low turnover disease pore water is 267 
lower, than normal animals.  Changes in pore water track closely to changes in cortical porosity, 268 
which is high in high turnover animals and low in low turnover animals at 35 weeks of age [14]. 269 
The changes in bound water, which have been shown to have predominant mechanical effect 270 
on bone [34], were unexpected and the mechanisms through which bound water is modulated in 271 
vivo remain unclear.  Bound water tends to be inversely related to mineralization and at least at 272 
30 weeks of age mineralization characteristics (determined by Raman spectroscopy) are not 273 
different from controls [16].  It is possible that mineral has changed by week 35 in these animals 274 
yet unfortunately tissue is not available for such analyses. Also, as intracortical porosity 275 
increases, there is more pore water but less matrix interactions with water molecules.  This is 276 
confirmed in the current work by the positive correlation between pore water and porosity (R = 277 
0.69).  278 
 Both AGE levels and bone hydration have been documented as having significant 279 
effects on bone mechanical properties.  Increasing AGE levels either in vitro, or in vivo, are 280 
inversely related to bone toughness – the ability of the bone tissue to absorb energy before 281 
fracture [23, 49].  Reductions in bone toughness reflect a bone that fractures more easily and in 282 
a more brittle fashion [50].  Conversely to AGEs, modulating bone hydration (specifically bound 283 
water) has been shown to have a positive relationship to bone toughness [34, 51].  Estimation of 284 
material-level mechanical properties in the current study shows that both high and low turnover 285 
disease lower bone toughness relative to normal animals, with only the lower turnover animals 286 
reaching statistical significance (Table 1).  Interestingly, these two conditions had contrasting 287 
effects on pore and bound water, as well as enzymatically-mediated crosslinks.  The only 288 
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common feature of the two conditions was a significant increase in levels of AGEs (pentosidine).  289 
Skeletal pentosidine was negatively correlated to bone toughness (r = -0.57; Figure 3B).  While 290 
we cannot definitively conclude that the higher AGE levels are fully responsible for the 291 
biomechanical phenotype, the results of this work suggest it is an outcome that should be a 292 
primary focus in future studies. 293 
 In conclusion, using an animal model of progressive chronic kidney disease, we have 294 
shown that both collagen crosslinking and skeletal hydration are affected in late-stage renal 295 
disease.  Although both of these variables are known to play roles in bone mechanical 296 
properties, the data suggest that accumulation on non-enzymatic collagen crosslinks may be a 297 
key change that is responsible for altering mechanical properties associated with late-stage 298 
disease progression. 299 
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FIGURE LEGENDS 314 
Figure 1.  High-turnover CKD associated changes in skeletal collagen crosslinking and tissue 315 
hydration.  (A) Enzymatic collagen cross-links (pyridinoline, PYD and deoxypyridinoline, DPD) 316 
were significantly lower in CKD compared to normal littermates.  (B) Pentosidine, an advanced 317 
glycation end product, was found in significantly higher concentrations in CKD bone compared 318 
to normal.  (C) Pore water fraction was significantly higher and bound water fraction significantly 319 
lower in CKD animals compared to normal.  * p < 0.05 compared to normal animals. 320 
 321 
Figure 2.  Low-turnover CKD associated changes in skeletal collagen crosslinking and tissue 322 
hydration.  (A) The enzymatic collagen cross-link (deoxypyridinoline, DPD) was significantly 323 
higher than normal in low-turnover disease; pyridinoline, PYD was unaffected. (B) Pentosidine, 324 
an advanced glycation end product, was found in significantly higher concentrations in CKD 325 
bone compared to normal.  (C) Pore water fraction was significantly lower and bound water 326 
fraction significantly higher in CKD animals compared to normal.  * p < 0.05 compared to normal 327 
animals. 328 
Figure 3.  Correlations between skeletal pentosidine levels and kidney function (A) and 329 
mechanical properties (B).  As both high and low turnover CKD models were shown to have 330 
higher pentosidine levels compared to normal we explored the relationship between kidney 331 
function and pentosidine.  This relationship was statistically significant (r = 0.68, p < 0.001).  332 
Given the known role of pentosidine in modulation of mechanical properties we also explored 333 
the relationship between pentosidine and bone toughness (B).  This relationship was statistically 334 
significant (r = -0.57, p = 0.002). 335 
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 337 
Table 1.  Femoral diaphysis morphology and calculated material-level biomechanical properties  338 
 339 
 Normal  High turnover 
CKD 
Low turnover  
CKD 
Bone diameter, mm 3.7 ± 0.2 3.6 ± 0.2 3.7 ± 0.1 
Porosity, % 0.1 ± 0.1 4.1 ± 5.4 * 0.5 ± 0.2 * 
Cross-sectional 
moment of inertia, mm4 
10.1 ± 1.5 8.56 ± 0.9 * 11.1 ± 1.4 
Ultimate stress, MPa 180 ± 17 140 ± 25 * 176 ± 27  
Modulus, MPa 6777 ± 831 6609 ± 750 6701 ± 880  
Toughness, MJ/m3 5.3 ± 1.1 4.2 ± 1.8  3.9 ± 0.7 * 
 340 
Values are presented as mean ± standard deviation. 341 
* p < 0.05 versus normal controls. 342 
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